Revolution Medicines This Year: Bulls and Bears for RVMD
Investors are buzzing about Revolution Medicines this year as its RAS-focused cancer programs advance. This article l...
Discover cash back credit cards that do not charge annual fees. Start saving while earning rewards!
26,411 articlesInvestors are buzzing about Revolution Medicines this year as its RAS-focused cancer programs advance. This article l...
Starboard Value’s effort at Dynatrace tests whether the observability software maker can turn around on its own or be...
Zscaler is steering its platform toward AI-driven security, aiming to reshape enterprise defense and investor returns...
A hantavirus outbreak can spark biotech chatter, but three solid realities—limited demand, tough development paths, a...
Stocks slid Friday as investors weighed whether AI-driven growth can sustain lofty valuations. Analysts warn this cou...
Alphabet stock looks undervalued as the tech giant rides a fresh wave of AI monetization, beating quarterly targets a...
Global markets surged after President Trump hinted at de-escalation in Iran, easing oil risks and boosting equities. ...
A new Belden stake filed with the SEC shows an investment firm buying $89.5 million worth of shares. This article bre...
When executives cash out after a stock's triple-digit run, it can raise questions for investors. This guide explains ...
A new player in the chip foundry race is signaling aggressive pricing. If a potential rival wants undercut, investors...
When the PC market slows, smart investors look beyond laptops. A new wave of winners emerges—from memory makers to AI...
Palantir's 2025 results set a high-growth trajectory, but investors want to know how the stock could perform by 2030....